Cargando…
Post-authorisation safety study of burosumab use in paediatric, adolescent and adult patients with X-linked hypophosphataemia: rationale and description
BACKGROUND: X-linked hypophosphataemia (XLH) is a rare, inherited, phosphate-wasting disorder that elevates fibroblast growth factor 23 (FGF23), causing renal phosphate-wasting and impaired active vitamin D (1,25(OH)(2)D) synthesis. Disease characteristics include rickets, osteomalacia, odontomalaci...
Autores principales: | Brandi, Maria Luisa, Ariceta, Gema, Beck-Nielsen, Signe Sparre, Boot, Annemieke M., Briot, Karine, de Lucas Collantes, Carmen, Emma, Francesco, Giannini, Sandro, Haffner, Dieter, Keen, Richard, Levtchenko, Elena, Mӓkitie, Outi, Nilsson, Ola, Schnabel, Dirk, Tripto-Shkolnik, Liana, Zillikens, M. Carola, Liu, Jonathan, Tudor, Alina, Mughal, M. Zulf |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9445456/ https://www.ncbi.nlm.nih.gov/pubmed/36082134 http://dx.doi.org/10.1177/20406223221117471 |
Ejemplares similares
-
The International X-Linked Hypophosphatemia (XLH) Registry: first interim analysis of baseline demographic, genetic and clinical data
por: Ariceta, Gema, et al.
Publicado: (2023) -
The international X-linked hypophosphataemia (XLH) registry (NCT03193476): rationale for and description of an international, observational study
por: Padidela, Raja, et al.
Publicado: (2020) -
Burosumab for X-linked hypophosphataemia
Publicado: (2021) -
FGF23 and its role in X-linked hypophosphatemia-related morbidity
por: Beck-Nielsen, Signe Sparre, et al.
Publicado: (2019) -
Benefit of burosumab in adults with X-linked hypophosphataemia (XLH) is maintained with long-term treatment
por: Kamenicky, Peter, et al.
Publicado: (2023)